Stephen S G Ferguson
Overview
Explore the profile of Stephen S G Ferguson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
115
Citations
2746
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rezaei R, Boulton S, Ahmadi M, Petryk J, Da Silva M, Kooshki Zamani N, et al.
Nat Biomed Eng
. 2024 Nov;
PMID: 39609558
Optimization of oncolytic viruses for therapeutic applications requires the strategic removal or mutagenesis of virulence genes alongside the insertion of transgenes that enhance viral replication, spread and immunogenicity. However, the...
2.
Abd-Elrahman K, Beaulieu J, Ferguson S
Front Cell Dev Biol
. 2024 Mar;
12:1388514.
PMID: 38481531
No abstract available.
3.
Abd-Elrahman K, Colson T, Sarasija S, Ferguson S
Biomed Pharmacother
. 2024 Mar;
173:116388.
PMID: 38460371
Alzheimer's disease (AD) is the most prevalent type of dementia, disproportionately affecting females, who make up nearly 60% of diagnosed cases. In AD patients, the accumulation of beta-amyloid (Aβ) in...
4.
Xing V, Biggar K, Ferguson S, Hayley S
Mol Brain
. 2024 Feb;
17(1):9.
PMID: 38360671
One of the main hallmarks of Parkinson's disease (PD) is abnormal alpha-synuclein (α-syn) aggregation which forms the main component of intracellular Lewy body inclusions. This short report used preformed α-syn...
5.
Li S, Colson T, Chen J, Abd-Elrahman K, Ferguson S
Mol Brain
. 2023 Sep;
16(1):67.
PMID: 37726802
Huntington's Disease (HD) is an inherited autosomal dominant neurodegenerative disorder that leads to progressive motor and cognitive impairment due to the expansion of a polyglutamine (CAG) repeat in the N-terminal...
6.
Ibrahim K, El Mestikawy S, Abd-Elrahman K, Ferguson S
J Neurosci
. 2023 Apr;
43(23):4365-4377.
PMID: 37055181
Huntington's disease (HD) is an autosomal-dominant neurodegenerative disease characterized by progressive motor and cognitive impairments, with no disease-modifying therapies yet available. HD pathophysiology involves evident impairment in glutamatergic neurotransmission leading...
7.
Li S, Abd-Elrahman K, Ferguson S
Pharmacol Ther
. 2022 Aug;
239:108275.
PMID: 36038019
Glutamate is the primary excitatory neurotransmitter in the brain and plays critical roles in all aspects of neuronal function. Disruption of normal glutamate transmission has been implicated in a variety...
8.
Ibrahim K, El Mestikawy S, Abd-Elrahman K, Ferguson S
eNeuro
. 2022 Apr;
9(3).
PMID: 35443989
Type 3 vesicular glutamate transporter (VGLUT3) represents a unique modulator of glutamate release from both nonglutamatergic and glutamatergic varicosities within the brain. Despite its limited abundance, VGLUT3 is vital for...
9.
Li S, Colson T, Abd-Elrahman K, Ferguson S
Front Mol Neurosci
. 2022 Feb;
15:801757.
PMID: 35185467
Huntington's disease (HD) is an inherited autosomal dominant neurodegenerative disorder that leads to progressive motor and cognitive impairment. There are currently no available disease modifying treatments for HD patients. We...
10.
Abd-Elrahman K, Sarasija S, Colson T, Ferguson S
Br J Pharmacol
. 2021 Nov;
179(8):1769-1783.
PMID: 34820835
Background And Purpose: Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive decline, and women account for 60% of diagnosed cases. β-Amyloid (Aβ) oligomers are considered the principal...